Patient demographic and baseline characteristics in the full analysis set
| Characteristic | Placebo (n=179) | ASU-E (n=166) | Total (n=345) |
|---|---|---|---|
| Gender (% women) | 56 | 51 | 54 |
| Age (years) (mean (SD)) | 62.7 (8.0) | 61.6 (7.9) | 62.2 (7.9) |
| BMI (kg/m2) (mean (SD)) | 26.8 (4.4) | 27.0 (4.1) | 26.9 (4.2) |
| Delay since 1st symptoms (years) (mean (SD)) | 4.3 (4.6) | 4.4 (5.6) | 4.3 (5.1) |
| Delay since regular symptoms (years) (mean (SD)) | 1.6 (2.0) | 1.6 (1.8) | 1.6 (1.9) |
| Other osteoarthritic sites (% yes) | 56 | 50 | 53 |
| Concomitant medications (% yes) | 82 | 80 | 81 |
| Kellgren–Lawrence grade (n (%)) | |||
| I | 12 (6.7) | 19 (11.4) | 31 (9) |
| II | 99 (55.3) | 88 (53.0) | 187 (54.2) |
| III | 66 (36.9) | 59 (35.5) | 125 (36.2) |
| IV | 2 (1.1) | 0 | 2 (0.6%) |
| Location of JSN at narrowest site (n (%)) | |||
| Superolateral | 99 (55.3) | 80 (48.2) | 179 (51.9) |
| Superomedial | 42 (23.5) | 40 (24.1) | 82 (23.8) |
| Superior global | 38 (21.2) | 46 (27.7) | 84 (24.3) |
| JSW at narrowest site of target hip (mm) (mean (SD)) | 2.76 (0.9) | 2.85 (0.9) | 2.81 (0.9) |
| Lequesne Index (normalised 0–100) (mean (SD)) | 30.4 (10.0) | 30.0 (8.4) | 30.2 (9.3) |
| WOMAC pain score (0–100 mm) (mean (SD)) | 32.7 (20.6) | 31.6 (18.6) | 32.2 (19.7) |
| WOMAC stiffness score (0–100 mm) (mean (SD)) | 36.2 (25.3) | 35.4 (23.5) | 35.8 (24.4) |
| WOMAC function score (0–100 mm) (mean (SD)) | 31.9 (21.5) | 31.4 (20.5) | 31.7 (21.0) |
| Global hip pain (0–100 mm) (mean (SD)) | 36.6 (23.9) | 37.4 (23.1) | 37.0 (23.5) |
| Global handicap, numerical scale (0–10) (mean (SD)) | 4.4 (1.9) | 4.4 (1.8) | 4.4 (1.9) |
| Patient's global assessment (0–100 mm) (mean (SD)) | 40.3 (27.9) | 40.4 (25.3) | 40.3 (26.6) |
ASU-E, avocado–soybean unsaponifiable—Expanscience; BMI, body mass index; JSN, joint space narrowing; JSW, joint space width; WOMAC, Western and Ontario MacMaster University.